ScreenerHero

DTIL Precision BioSciences, Inc.

NAS · US · Healthcare · Biotechnology · precisionbiosciences.com
6.250USD+0.81%Mkt Cap: 172.51M $P/E: —

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARC…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap172.51M USD
Enterprise Value111.68M USD
Revenue (TTM)45.05M USD
Gross Profit45.05M USD
Net Income (TTM)-45.72M USD
Revenue/Share2.21 USD
Last Price6.250 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.33
PEG—
EV/EBITDA-3.18
EV/Revenue2.48
P/S3.80
P/B3.62
EPS (TTM)-1.35
EPS (Forward)-1.86
52W Range
3.53045% of range9.620
52W High9.620 USD
52W Low3.530 USD
Profitability
Gross Margin100.00%
Oper. Margin-80.78%
EBITDA Margin-78.01%
Profit Margin-133.45%
ROE-49.57%
ROA-29.61%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.84M USD
CapEx (TTM)700.00K USD
FCF Margin-36.07%
FCF Yield-9.42%
Net Debt-59.45M USD
Net Debt/EBITDA1.69
Balance Sheet
Debt/Equity0.31
Current Ratio12.82
Quick Ratio12.26
Book Value/Sh1.71 USD
Cash/Share3.17 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2024
Analyst Consensus
Rating—
Target (Mean)29.40 USD
Upside (mean)+370.4%
Target Range18.00 USD – 60.00 USD
18.00+370.4% to mean60.00
# Analysts5
Ownership
Shares Out.27.60M
Float25.45M
Insiders8.04%
Institutions68.71%
Short Interest
Short Ratio8.5d
Short % Float8.25%
Short % Out.8.06%
Shares Short2.22M
Short (prev mo.)2.40M
Technical
SMA 507.256 (-13.9%)
SMA 2006.321 (-1.1%)
Beta1.27
S&P 52W Chg16.45%
Avg Vol (30d)246.20K
Avg Vol (10d)277.34K
Technical Indicators
RSI (14)38.0
MACD-0.3183
MACD Signal-0.3153
MACD Hist.-0.0029
BB Upper7.446 USD
BB Middle6.594 USD
BB Lower5.742 USD
BB Width25.84%
ATR (14)0.3707 USD
Vol Ratio (20d)0.67x